All News

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, discusses how clinical trials have evolved to address biological and sociological variables in patient health.

Insulin glargine-yfgn (Semglee; Viatris) presents the first opportunity for retail pharmacists to dispense a biosimilar to patients.

The FDA looks to address a lack of diversity in cancer drug trials.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses how the results of the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma may impact the treatment landscape.

The Prosacea Medicated Rosacea Gel is used to treat rosacea, redness, and acne.

Ismail Lourido Ali, JD, director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses which psychedelic drugs are currently under investigation for potential FDA approval.

Andrew Mulcahy, PhD, a senior policy researcher at RAND Corporation, discusses a recent report that showed the drug shortages in the United States may not be associated with problems in the global supply chain.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses how the diabetes DRIVE program compares with the SHC DRIVE models for flu and COVID-19 vaccinations.

Study indicates those who experienced a greater amount of stress from the COVID-19 pandemic had reduced information processing speed.

Chronic hypersensitivity pneumonitis is a long-term lung condition in which the interstitial tissue surrounding the alveoli of the lungs becomes inflamed and develops fibrosis.

Foot drop is a sign of an underlying neurological, muscular, or anatomical problem.

Trial court judge places limits on testimony of widow’s pharmacy expert witness and dismisses lawsuit.

Laura Lee Hall, PhD, president of the Center for Sustainable Health Care Quality and Equity (SHC), addresses what the SHC’s diabetes DRIVE toolkit is and how it helps to address disparities in diabetes disease burden and health outcomes.

Xanax is indicated for the acute treatment of generalized anxiety disorder and treatment of panic disorder with or without agoraphobia in adults.

Sarah Temkin, MD, of the Office of Research on Women’s Health (ORWH) at the National Institutes of Health (NIH), discusses how the NIH ORWH has helped to advance clinical research on biological and sociological variables.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the adverse events experienced by patients with newly diagnosed multiple myeloma who were administered daratumumab, carfilzomib, lenalidomide, and dexamethasone.

Tea tree oil is indicated for everyday use associated with its cleansing properties.

Despite demonstrating numerous benefits, semaglutide has also been linked to an increased incidence of diabetic retinopathy, which was initially reported in the SUSTAIN-6 trial.

David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.

The health of a pharmacy business is under attack from many directions, but retail pharmacies can take steps to alleviate some of this pressure to improve the health of their business.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Bladder cancer risk increases with age and is more common among men than women.

Study suggests that emergency physicians prescribe naloxone to patients who overdose.

Common triggers for atrial fibrillation include alcohol, caffeine, and less sleep.

Flatfeet develop after an injury or from the simple wear-and-tear stresses of age.

The emergency use authorization is based on data from the EPIC-HR trial, which showed that the drug significantly reduced the risk of hospitalization or death compared with the placebo.

The drug is available in both oral suspension and tablet dosage forms for use in individuals aged 18 years or younger.

The drug is the first and only oral therapy approved for the treatment of adult patients who are candidates for either phototherapy or systemic therapy.

The agency’s approval follows trial results demonstrating the superior efficacy of the cabotegravir long-acting injectable to a daily oral PrEP option in reducing the risk of infection.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.